Sanofi (SNY)
After hours:
| Previous close | 45.86 |
| Open | 46.28 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 46.21 - 47.06 |
| 52-week range | 36.91 - 58.10 |
| Volume | |
| Avg. volume | 2,495,998 |
| Market cap | 119.25B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 16.20 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.75 (3.81%) |
| Ex-dividend date | 26 May 2022 |
| 1y target est | N/A |
- GlobeNewswire
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone Paris, February 3, 2023 Q4 2022 sales growth of 2.6% at CER and business EPS(1) growth of 17.4% at CER Specialty Care grew 18.1% driven by Dupixent® (€2,402 million, +42.1%) and new product launchesVaccines sales (-16.3%) reflecting influenza and PPH sales phasing (Q3 influenza sales: up 32.4%) as well as ramp up of non-consolidated Vaxelis® salesGeneral Medicines core assets up 8.0%
- GlobeNewswire
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also significantly improved their ability to swallow compared to placebo Dupixent is now an option for the approximately 50,000 adults and adolescents living with severe uncontrolled eosinophilic esophagitis in the European Union (EU) Dupixent now approved to treat five diseases with underlying type 2 inflammation in the EU TARRYTOWN,
- GlobeNewswire
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also significantly improved their ability to swallow compared to placeboDupixent is now an option for the approximately 50,000 adults and adolescents living with severe uncontrolled eosinophilic esophagi
